Systemic and targeted therapy for advanced colon cancer (Q37345922)

19 August 2017

1 reference

title

Systemic and targeted therapy for advanced colon cancer (English)

1 reference

19 August 2017

Sanjay R Hegde

1

1 reference

PubMed ID

19072376

19 August 2017

Weijing Sun

series ordinal

2

1 reference

PubMed ID

19072376

19 August 2017

John P Lynch

series ordinal

3

1 reference

19 August 2017

1 February 2008

1 reference

Expert Review of Gastroenterology & Hepatology

19 August 2017

1 reference

19 August 2017

2

1 reference

19 August 2017

1

1 reference

19 August 2017

135-149

1 reference

19 August 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Systemic therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

A double-blind comparison of intensive course 5-fluorouracil by oral vs. intravenous route in the treatment of colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Clinical pharmacology of camptothecins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Angiogenesis: an organizing principle for drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Capecitabine plus oxaliplatin in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Gefitinib in colorectal cancer: if wishes were horses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

DCC: linking tumor suppressor genes and altered cell surface interactions in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

Combined Antiangiogenesis and Antiepidermal Growth Factor Receptor Targeting in the Treatment of Cancer: Hold Back, We Are Not There Yet

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474124.2.1.135

21 January 2018

Identifiers

DOI

10.1586/17474124.2.1.135

1 reference

19 August 2017

1 reference

PubMed ID

19072376